Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-
CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL),∼ …

Diffuse large B cell lymphoma represents the most common type of non-Hodgkin lymphoma.
Although the curability rate is high, around 40% of patients will relapse or exhibit refractory …

Abstract The European Society for Medical Oncology (ESMO) consensus conference on
mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June …

Most patients with Diffuse Large B-cell Lymphoma (DLBCL) are old (> 65 years of age) and
this population is expected to increase in the following years. A simplified geriatric …

Transplant‐ineligible relapsed/refractory (rr) diffuse large B‐cell lymphoma (DLBCL)
patients represent an unmet medical need. Polatuzumab vedotin (Pola), an anti‐CD79b …

Diffuse large B cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma,
accounting for approximately 30% of lymphoma cases in Canada. Although most patients …

The present study aims at defining the economic and organizational impacts of the
introduction of chimeric antigen receptor T-cell therapy (CAR-T) in Italy, for the management …

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common histotype in non
Hodgkin lymphoma, with a peak incidence in the sixth decade. The standard treatment for …

Background Studies suggest that immune checkpoint inhibitors may represent a promising
strategy for boosting immune responses and improving the antitumor activity of standard …

Background Patients affected by aggressive B-cell malignancies who are resistant to
primary or salvage chemoimmunotherapy have an extremely poor prognosis and limited …